Latest From Polymedco Inc.
Epigenomics has finally gained US FDA approval for its Epi proColon noninvasive colorectal cancer screening test, ending what has been a long, obstacle-filled journey for the German-US molecular diagnostics company.
UroSens Ltd. has developed a test that measures the presence of dividing cells in a urine sample, where there should be no dividing cells, and thus is indicative of cancer. The start-up's lead indication is bladder cancer, but it is exploring its use in other cancers, including prostate.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced September through October 2013.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced August-October 2013.
- In Vitro Diagnostics
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Polymedco Inc.
- Senior Management
- Andrew Cervasio, Pres.
- Contact Info
Phone: (914) 739-5400
510 Furnace Dock Rd.
Cortlandt Manor, NY 10567
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.